Europe Wound Care Market on Track for USD 8.4 Billion by 2033 at 4.1% Annual Growth

Market Overview

The Europe wound care market size was valued at USD 5.8 Billion in 2024 and is projected to reach USD 8.4 Billion by 2033. It is expected to grow at a CAGR of 4.1% during the forecast period from 2025 to 2033. Rising prevalence of chronic wounds, advancements in wound management technologies, and an aging population are key market drivers. Increased demand for innovative wound care products and supportive healthcare policies further contribute to the sustained growth of the market in Europe.

Download a sample copy of the report: https://www.imarcgroup.com/Europe-Wound-Care-Market/requestsample

Study Assumption Years

Base Year: 2024
Historical Year/Period: 2019-2024
Forecast Year/Period: 2025-2033

Europe Wound Care Market Key Takeaways

Current Market Size: USD 5.8 Billion (2024)
CAGR: 4.1% (2025-2033)
Forecast Period: 2025-2033
The market growth is driven by increasing chronic disorders like diabetes and vascular diseases in Europe.
Advancements in wound care solutions such as bioactive materials and vacuum-assisted closure systems improve recovery rates.
Increasing healthcare expenditures and favorable government initiatives enhance access and affordability of advanced wound care products.
The market experiences a growing shift towards advanced wound care products including foam dressings, hydrocolloid dressings, and film dressings.
The rising elderly population and chronic conditions are fueling the demand for home-based wound care solutions.

Market Growth Factors

Chronic diseases, especially diabetes and vascular disorders, rise in prevalence, which drives the Europe wound care market and increases the demand for wound care products. WHO reports diabetes mellitus appears often as a chronic disease in the WHO European Region. Europe has the highest prevalence of type 1 diabetes globally. It has been predicted that by 2045, one in ten people throughout the region will be affected. The increasing number of older people in the population increases demand for care, as older people are more prone to develop slow-healing wounds and pressure ulcers.

Technological advances in wound healing products, such as bioactive materials and vacuum-assisted closure (VAC) devices, are increasing the market growth, as such devices help to speed up the process of wound healing. Furthermore, the rise in awareness about the need for good wound care to reduce the incidence of infections increases growth. As minimally intrusive techniques gain acceptance, there is a need to avoid complications during recovery.

Furthermore, healthcare spending in Europe is rising, leading to greater access to advanced wound care products. According to industry estimates, healthcare spending in Europe is about 11% of GDP; about 7.9% of that is spent on medical technologies. The growth of the market is attributed to the government programs focusing on the patient and stringent reimbursement policies to make biologics and regenerative products affordable, along with increased clinical trials.

Request Customization: https://www.imarcgroup.com/request?type=report&id=11055&flag=E

Market Segmentation

By Product Type:

Advanced Wound Care Products:
Foam Dressing: Used for superior moisture retention and exudate management.
Hydrocolloid Dressing: Preferred for self-adherence and maintaining a moist wound environment.
Film Dressing: Serves as a semi-permeable covering protecting the wound.
Alginate Dressing: Used for highly exudating wounds.
Hydrogel Dressing: Provides hydration.
Collagen Dressing: Supports tissue regeneration.
Others
Surgical Wound Care Products:
Sutures
Staplers
Tissue Adhesive, Sealants and Hemostats
Anti-effective Dressing
Traditional Wound Care Products:
Medical Tapes: Ensure secure dressing placement.
Cleansing Agent: Essential for pre-treatment cleaning to reduce infection risks.
Active Wound Care Products:
Biological Skin Substitutes: Mimic natural tissue for severe wounds.
Topical Agents: Antimicrobial and growth factor-based formulations accelerating healing.
Wound Therapy Devices Products:
Negative Pressure Wound Therapy
Oxygen and Hyperbaric Oxygen Equipment
Electric Stimulation Devices
Pressure Relief Devices
Wound Assessment and Monitoring Devices
Others

By Wound Type:

Chronic Wounds:
Diabetic Ulcers: Driven by increasing diabetes and obesity cases.
Pressure Ulcers: Common in immobilized elderly patients.
Venous Leg Ulcers: Associated with chronic venous insufficiency; need compression therapies.
Others
Acute Wounds:
Surgical Traumatic Wounds: Rising surgical procedures stimulate demand.
Burns: Prevalent in industrial and domestic accidents requiring specialized care.

By End User:

Hospitals and Clinics: Manage acute and complex wounds using advanced technologies.
Long-Term Care Facilities: Focus on prevention and ongoing management, especially for pressure ulcers.
Home Care Setting: Growing patient preference for portable and user-friendly wound care solutions.
Others

Regional Insights

Germany is the dominant market for wound care in Europe, supported by advanced healthcare infrastructure and high adoption of innovative wound care products. It faces a rising prevalence of chronic wounds such as diabetic foot ulcers and pressure ulcers due to an aging population. Germany also benefits from strong clinical research and development, favorable reimbursement policies, and widespread healthcare awareness, making it a crucial contributor to the regional market growth.

Recent Developments & News

In May 2024, Kerecis, a Europe-based company specializing in fish skin for wound care, announced plans to present an industry-backed symposium on intact fish skin for chronic wound care at the European Wound Management Association (EWMA). RELIEF THERAPEUTICS Holding SA, a Switzerland-based biopharmaceutical firm, announced receipt of a Notice of Allowance from the European Patent Office (EPO) for its patent on "Therapeutic Uses of Oxidizing Hypotonic Acid Solutions," covering its hypochlorous acid solutions and investigational wound treatment drug RLF‐TD011. In August 2024, Amferia AB, a Swedish antimicrobial company, partnered with Biokema SA, a Swiss animal health firm, to commercialize its antimicrobial wound care technology in Switzerland, launching products by early 2025 to address antibiotic resistance in veterinary wound care.

Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=11055&flag=C

Key Players

Amferia AB
Biokema SA
Kerecis
RELIEF THERAPEUTICS Holding SA

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Contact Us

IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302

About Us

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.